Mark Muthiah
@DrMarkMuthiah
Followers
472
Following
231
Media
9
Statuses
154
Transplant hepatologist in National University Hospital, Singapore. Interest in NAFLD, NASH and liver transplantation.
Joined October 2020
Great time in Bali @APASLnews stc on portal hypertension. Many practical lessons to take home to patients. But the highlight certainly had to be @JasmohanBajaj and his killer moves! Really great organization by #rinaldilesmana. @VCU_Liver @JSGracia @drshivsarin @ashok_doctor
0
2
21
Thanks for organizing this!
0
0
2
Excellent science and amazing hospitality at the KASL 2024. Grateful to the organizers for the invitation to speak on #masld. Glad to have met friends, both old and new! #livertwitter
1
2
25
Understanding and addressing the intertwined factors in #MASLD and #T2D can lead to better management and prevention of cardiometabolic complications. https://t.co/f0CPOtrv4x
0
10
43
Great study @DrHuangDQ
New study in @JHepatology highlights widespread neglect of chronic Hepatitis B, especially among women & Asian minorities in the West. With the @WHO's ambitious goal to eliminate viral hepatitis by 2030, targeted efforts are urgently needed to bridge this gap in healthcare
0
0
6
HBV antivirals prevent HCC. What % of pts with HBV get an adequate evaluation to assess treatment eligibility based on @AASLDtweets criteria? What % receive treatment? 👩🦰 disadvantaged! We evaluated 🔼 in 25 centers/>12K pts @JHepatology free link: https://t.co/DXHWPsfh2g
0
8
22
Delve into the complex world of #liver fibrosis in #MASLD #MASH. This comprehensive @MolAspMed review by Maurizio Parola & @MassimoPinzani covers everything from pathophysiology to the latest in diagnostics and therapies. A must-read for those seeking depth and detail in liver
0
8
21
Amazing work! Do you think anti viral therapy should be protocolized when discussing HBV cases in tumour board meetings?
New data @JCO_ASCO We examined antiviral therapy utilization and 10-year outcomes in resected HCC ✅ Antiviral therapy a/w 40% and 80% increase in 10-year survival for HBV- and HCV-HCC BUT ‼️ Utilized in <50% @ASCO @APASLnews @AASLDtweets
https://t.co/YZSYQEKBIx
2
1
6
📢 Just In!" Defining an approach for therapeutic strategies in MASLD after liver transplantation" | Accelerated fibrosis, high metabolic burden—yet, no regulatory pathway for therapeutics. Bridge the gap for improved post-LT outcomes!🩺🌐 https://t.co/HCekamWs4p
@AASLDtweets
0
4
5
Thanks for the opportunity to collaborate on this piece. from 2010-2019, ⬆️BMI led to: - a 35 % ⬆️ in ☠️ from cancers and 34 % ⬆️ in DALYs - Europe had the greatest number of deaths due to this - Liver cancer is the fastest-growing cause of cancer mortality due to this
1
16
33
#GITwitter #LiverTwitter 🔥 #Ultrasound and #MRI is used for screening #HCC... but how is the overall quality of both modality for #HCC screening🤔? @Nicholas_Syn @DrHuangDQ @DrLoomba @DrMarkMuthiah Free to read!: https://t.co/fkGxhNQ6vC !
0
7
18
🌍 New study on #NAFLD: From 2010 to 2019, 228M cases, 87,230 deaths, and 1.46M DALYs globally in #elderly. The Western Pacific region hit hardest. Shockingly high prevalence, especially in men. Let's address this urgent global health concern together. https://t.co/mSGGVhBW3T
onlinelibrary.wiley.com
The burden of nonalcoholic fatty liver disease has been on the rise among the elderly, particularly in the Western Pacific region.
0
5
15
📊 Latest study from @TheLiverFound highlights: Cardiovascular risk up by 43%. Metabolic disorders surge (75%-156%). Kidney disease risk increases by 38%. Cancer risk up by 54%. Call for a holistic healthcare approach. 💪🏥 🔗 Read the full study: https://t.co/Ju4rqgt7SW
1
1
19
Are NASH patients disadvantaged on liver transplant wait lists? 🤔
0
0
8
It’s not too late to register! Click https://t.co/Fdg6h1FiJo to book your slot and catch the latest insights from our international and local faculty! Join us and enjoy the end of summer in the Philippines! See you there! #LiverTwitter
@APASLnews
0
4
0
I'll send to my friend @DrHuangDQ to treat. There is a certain clinic on Thursdays eagerly awaiting his return!
Does treating hepatitis B in the indeterminate phase (eg. ⬆️ DNA, ⬇️ALT) reduce HCC risk? ▶️14 centers (US, Europe, Asia) ▶️10-year HCC incidence: 15% (untreated) vs 4% (treated) ▶️~70% reduction in HCC ⁉️ Do you treat? @HEP_Journal @AASLDtweets
https://t.co/ZI3G4LdlSY
0
1
11
Finally get to meet my good friend @NoureddinMD in person at #ilts2023. Amazing summary of treatment strategies for NASH.. #livertwitter @dreunicetan @ChengHanNg @WenHuiLim4 @DarrenTanJH @_ILTS_
0
0
13
Important work emphasising the role of nafld / fibrosis in extrahepatic conditions..
In a #cohort of acute #myocardial #infarction pts: 1⃣1/5 had hepatic #steatosis; of whom, 2/5 had advanced #fibrosis 2⃣Hepatic steatosis a/w DM, HTN, HLD 3⃣Hepatic steatosis and fibrosis had higher mortality ➡️ https://t.co/EMpwP260XY
#Cardiotwitter #livertwitter
0
2
11